1.85 USD
-0.13 (-6.57%)
We assign a fundamental rating of 1 out of 10 to VERO. VERO was compared to 188 industry peers in the Health Care Equipment & Supplies industry. VERO has a bad profitability rating. Also its financial health evaluation is rather negative. VERO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
VERO had negative earnings in the past year.
VERO had a negative operating cash flow in the past year.
VERO had negative earnings in each of the past 5 years.
VERO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -65.52%, VERO is not doing good in the industry: 70.74% of the companies in the same industry are doing better.
With a Return On Equity value of -1776.32%, VERO is not doing good in the industry: 87.77% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.52% | ||
| ROE | -1776.32% | ||
| ROIC | N/A |
ROA(3y)-47.85%
ROA(5y)-42.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VERO has a better Gross Margin (64.88%) than 67.02% of its industry peers.
VERO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VERO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERO has more shares outstanding
VERO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VERO has been reduced compared to a year ago.
2.2 Solvency
VERO has an Altman-Z score of -8.02. This is a bad value and indicates that VERO is not financially healthy and even has some risk of bankruptcy.
VERO's Altman-Z score of -8.02 is on the low side compared to the rest of the industry. VERO is outperformed by 75.00% of its industry peers.
A Debt/Equity ratio of 6.82 is on the high side and indicates that VERO has dependencies on debt financing.
VERO's Debt to Equity ratio of 6.82 is on the low side compared to the rest of the industry. VERO is outperformed by 87.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.82 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.02 |
ROIC/WACCN/A
WACC2.93%
2.3 Liquidity
A Current Ratio of 1.10 indicates that VERO should not have too much problems paying its short term obligations.
VERO has a Current ratio of 1.10. This is amonst the worse of the industry: VERO underperforms 87.23% of its industry peers.
A Quick Ratio of 0.71 indicates that VERO may have some problems paying its short term obligations.
VERO has a Quick ratio of 0.71. This is amonst the worse of the industry: VERO underperforms 87.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.1 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 44.64% over the past year.
Looking at the last year, VERO shows a very negative growth in Revenue. The Revenue has decreased by -15.09% in the last year.
VERO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.10% yearly.
EPS 1Y (TTM)44.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.78%
Revenue 1Y (TTM)-15.09%
Revenue growth 3Y-15.01%
Revenue growth 5Y-10.1%
Sales Q2Q%-8.2%
3.2 Future
The Earnings Per Share is expected to grow by 39.27% on average over the next years. This is a very strong growth
Based on estimates for the next years, VERO will show a decrease in Revenue. The Revenue will decrease by -0.18% on average per year.
EPS Next Y76.72%
EPS Next 2Y39.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.41%
Revenue Next 2Y-0.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VERO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VERO's earnings are expected to grow with 39.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.27%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VERO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:VERO (12/1/2025, 8:00:02 PM)
1.85
-0.13 (-6.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners13.23%
Inst Owner Change35.1%
Ins Owners0.78%
Ins Owner Change0%
Market Cap3.44M
Revenue(TTM)64.83M
Net Income(TTM)-41.34M
Analysts45.71
Price TargetN/A
Short Float %5.21%
Short Ratio0.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.91%
Min EPS beat(2)-21.43%
Max EPS beat(2)-20.38%
EPS beat(4)0
Avg EPS beat(4)-14.09%
Min EPS beat(4)-21.43%
Max EPS beat(4)-4.58%
EPS beat(8)0
Avg EPS beat(8)-30.66%
EPS beat(12)2
Avg EPS beat(12)-21.75%
EPS beat(16)3
Avg EPS beat(16)-28.76%
Revenue beat(2)1
Avg Revenue beat(2)0.46%
Min Revenue beat(2)-4.4%
Max Revenue beat(2)5.33%
Revenue beat(4)1
Avg Revenue beat(4)-5.75%
Min Revenue beat(4)-14.85%
Max Revenue beat(4)5.33%
Revenue beat(8)2
Avg Revenue beat(8)-5.83%
Revenue beat(12)4
Avg Revenue beat(12)-3.95%
Revenue beat(16)5
Avg Revenue beat(16)-4.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-48.84
EYN/A
EPS(NY)-4.67
Fwd EYN/A
FCF(TTM)-10.15
FCFYN/A
OCF(TTM)-10.01
OCFYN/A
SpS32.32
BVpS1.25
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.52% | ||
| ROE | -1776.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.88% | ||
| FCFM | N/A |
ROA(3y)-47.85%
ROA(5y)-42.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-0.33%
F-Score4
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 6.82 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.11% | ||
| Cap/Sales | 0.45% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.1 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | -8.02 |
F-Score4
WACC2.93%
ROIC/WACCN/A
Cap/Depr(3y)4.54%
Cap/Depr(5y)6.03%
Cap/Sales(3y)0.23%
Cap/Sales(5y)0.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.78%
EPS Next Y76.72%
EPS Next 2Y39.27%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.09%
Revenue growth 3Y-15.01%
Revenue growth 5Y-10.1%
Sales Q2Q%-8.2%
Revenue Next Year-9.41%
Revenue Next 2Y-0.18%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.82%
OCF growth 3YN/A
OCF growth 5YN/A
VENUS CONCEPT INC / VERO FAQ
What is the ChartMill fundamental rating of VENUS CONCEPT INC (VERO) stock?
ChartMill assigns a fundamental rating of 1 / 10 to VERO.
What is the valuation status for VERO stock?
ChartMill assigns a valuation rating of 1 / 10 to VENUS CONCEPT INC (VERO). This can be considered as Overvalued.
Can you provide the profitability details for VENUS CONCEPT INC?
VENUS CONCEPT INC (VERO) has a profitability rating of 1 / 10.
Can you provide the financial health for VERO stock?
The financial health rating of VENUS CONCEPT INC (VERO) is 1 / 10.